Abstract
Background Deep brain structures are supplied by perforating arteries, these arteries are too thin to be observed with non-invasive and widely available clinical imaging methods. In Moya Moya disease, main arteries in the base of the brain progressively narrowed, and perforating arteries grow densely and tortuously to compensate the lack of blood supply in deep brain structures.
Purpose The aim of this study is to evaluate the efficacy of transcranial ultrasound localization microscopy (ULM) in visualizing perforating arteries, utilizing a standard low-frame-rate ultrasound clinical scanner and contrast sequences commonly employed in hospital settings.
Methods This prospective single-center study included ischemic stroke patients not related to perforating arteries, i.e. control patients, and Moya Moya disease patients (n° 2022-A02486-37). Contrast-enhanced ultrasound sequences (CEUS) were performed by an experienced neurologist and the images acquired were used to perform post-processing ULM. ULM density maps, i.e. number of microbubbles tracked per pixel, were compared with conventional 3T TOF MRI and color Doppler imaging (one-way ANOVA test). We also compared ULM density maps between the control and Moya Moya groups (two-sided parametric Student’s t-tests, or Mann-Whitney test).
Results We included a group of 15 control patients and another group of 9 Moya Moya patients between March 2023 and March 2024. The patients had an average age of 45 years with 65% of them being male. Perforating arteries were captured on all subjects, with a mean diameter of 0.8 ± 0.3 mm in control patients, while it was not so far possible with TOF MRI or color Doppler (P < 0.05). Moreover, ULM enabled the differentiation between healthy subjects and those with Moya Moya disease through track mean distance (P = 0.05).
Conclusions Using a low-frame-rate ultrasound scanner, CEUS and accessible post-processing tools, we have demonstrated that transcranial ULM can facilitate the visualization and characterization of perforating arteries, even in cases where they were previously undetectable using standard non-invasive imaging techniques. We speculate that with the advent of high-frame-rate 3D ULM, this technique may find widespread utility in hospitals.
Key Results
- 2D low-frame rate Ultrasound Localization Microscopy (ULM) allows visualization of perforating arteries, i.e. diameter of 0.8 ± 0.3 mm.
- ULM described vessels that were not visible in conventional imaging techniques, i.e. TOF MRI and color Doppler.
- ULM reconstruction and quantification of the perforating arteries enabled the pathological group (Moya Moya) to be distinguished from control subjects.
Summary statement Transcranial 2D ULM performed with a standard low frame-rate clinical ultrasound scanner enabled visualization and morphological description of perforating arteries. The study involved 24 subjects, including 9 Moya Moya patients.
Competing Interest Statement
O.C. holds patents in the field of ultrasound localization microscopy and is a cofounders and shareholders of the ResolveStroke startup. Other authors have nothing to declare.
Funding Statement
This study was funded by the European Research Council under the European Union Horizon H2020 program (ERC Consolidator grant agreement No 772786-ResolveStroke).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This clinical study was approved by the 'Comite de Protection des Personnes (CPP) Ouest IV - Nantes' (Maison de la Recherche en Sante, 44000 NANTES France) on March 9, 2023. The SI identification number is: 22.04689.000108. The national identification number is: 2022-A02486-37. The ClinicalTrials.gov ID is: NCT05785598.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Patients imaging data are not available due to ethical, medicamedical, and legislative considerations toward personal information.
Abbreviations
- MB
- microbubbles
- US
- ultrasound
- ULM
- ultrasound localization microscopy
- CEUS
- contrast-enhanced ultrasound
- TOF
- MRI time of flight magnetic resonance imaging
- LSA
- lenticulostriate arteries
- MCA
- middle cerebral artery
- ACA
- anterior cerebral artery
- PCA
- posterior cerebral artery